1,721,119 research outputs found
Best Oral Presentation during the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis 18th Annual Conference of Rehabilitation in Multiple Sclerosis
No full text
Accidental falls and imbalance in multiple sclerosis: diagnostic challenges, neuropathological features and treatment strategies
No full textDimethyl fumarate in the management of multiple sclerosis: Appropriate patient selection and special considerations
Full text linkDelayed-release dimethyl fumarate (DMF), also known as gastroresistant DMF, is the most recently approved oral disease-modifying treatment (DMT) for relapsing multiple sclerosis. Two randomized clinical trials (Determination of the Efficacy and Safety of Oral Fumarate in Relapsing–Remitting MS [DEFINE] and Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis [CONFIRM]) demonstrated significant efficacy in reducing relapse rate and radiological signs of disease activity, as seen on magnetic resonance imaging. The DEFINE study also indicated a significant effect of DMF on disability worsening, while the low incidence of confirmed disability worsening in the CONFIRM trial rendered an insignificant reduction among the DMF-treated groups when compared to placebo. DMF also demonstrated a good safety profile and acceptable tolerability, since the most common side effects (gastrointestinal events and flushing reactions) are usually transient and mild to moderate in severity. Here, we discuss the place in therapy of DMF for individuals with relapsing multiple sclerosis, providing a tentative therapeutic algorithm to manage newly diagnosed patients and those who do not adequately respond to self-injectable DMTs. Literature data supporting the potential role of DMF as a first-line therapy are presented. The possibility of using DMF as switching treatment or even as an add-on strategy in patients with breakthrough disease despite self-injectable DMTs will also be discussed. Lastly, we argue about the role of DMF as an exit strategy from natalizumab-treated patients who are considered at risk for developing multifocal progressive leukoencephalopathy
The clinical relevance of force platform measures in multiple sclerosis: a review. Mult Scler Int. 2013;2013:756564. doi: 10.1155/2013/756564. Epub 2013 May 19.
No full textACCIDENTAL FALLS AND IMBALANCE IN MULTIPLE SCEROSIS: DIAGNOSTIC CHALLENGES, NEUROPATHOLOGICAL FEATURES, AND TREATMENT STRATEGIES
Full text linkLack of balance is common in Multiple Sclerosis (MS) and is among the most disabling symptoms, since it reduces mobility and independence, leads to falls and injuries, and impacts upon overall quality of life. In this research we aimed to report the efforts made to: (i) establish an objective and reliable method to measure imbalance in MS by means of static posturography; (ii) estimate the role of this method in predicting patients at risk of falls; (iii) investigate the neuropathological features leading to imbalance in MS by combining static posturography and conventional / non-coventional magnetic resonance imaging; (iv) verify the effectiveness of visuo-proprioceptive rehabilitation in reducing balance deficit and risk of falls in these patients
Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis
No full text- …
